Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000921895-25-001976
Filing Date
2025-07-09
Accepted
2025-07-09 16:39:22
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 21852
2 JOINT FILING AGREEMENT ex991to13g07422nktr_070925.htm EX-99.1 15146
  Complete submission text file 0000921895-25-001976.txt   38981
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Subject) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-45385 | Film No.: 251114001
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Business Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

EIN.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6282 Investment Advice
(CF Office: 02 Finance)